COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical O
COPENHAGEN, Denmark—Marked prolongation of progression free survival (PFS) in all groups of patients with platinum-sensitive recurrent ovarian cancer was reported at the European Society for Medical Oncology 2016 congress in findings from the double-blind phase 3 European Network of Gynaecological Oncology Trial groups (ENGOT-OV16/NOVA) trial of the oral poly adenosine-diphosphate–ribose polymerase (PARP) 1/2 inhibitor, niraparib, compared with placebo in patients with platinum-sensitive recurrent ovarian cancer.
Mansoor Raza Mirza MD, Chief Oncologist at Copenhagen University Hospital and Medical Director of the Nordic Society of Gynaecologic Oncology discusses the findings with Peter Goodwin.
http://www.nejm.org/doi/full/10.1056/NEJMoa1611310#t=articleTop
Tags
Related Episodes
Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity
Refractory Ovarian Cancer Yields to Claudin 6 Targeted Antibody Drug Conjugate
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib
BRCA1/2 Ovarian Cancer—Three Years Disease Free with First-Line Olaparib MUNICH—An “unprecedented improvement” in progression free survival (PFS) was observed in the randomized controlled